825 related articles for article (PubMed ID: 17021963)
1. Analysis of amorphous and nanocrystalline solids from their X-ray diffraction patterns.
Bates S; Zografi G; Engers D; Morris K; Crowley K; Newman A
Pharm Res; 2006 Oct; 23(10):2333-49. PubMed ID: 17021963
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in the characterization of amorphous pharmaceuticals by X-ray diffractometry.
Thakral S; Terban MW; Thakral NK; Suryanarayanan R
Adv Drug Deliv Rev; 2016 May; 100():183-93. PubMed ID: 26712710
[TBL] [Abstract][Full Text] [Related]
3. Polymorphic form of piroxicam influences the performance of amorphous material prepared by ball-milling.
Naelapää K; Boetker JP; Veski P; Rantanen J; Rades T; Kogermann K
Int J Pharm; 2012 Jun; 429(1-2):69-77. PubMed ID: 22433471
[TBL] [Abstract][Full Text] [Related]
4. Formation, Physicochemical Characterization, and Thermodynamic Stability of the Amorphous State of Drugs and Excipients.
Martino PD; Magnoni F; Peregrina DV; Gigliobianco MR; Censi R; Malaj L
Curr Pharm Des; 2016; 22(32):4959-4974. PubMed ID: 27464724
[TBL] [Abstract][Full Text] [Related]
5. Solid-state characterization of amorphous and mesomorphous calcium ketoprofen.
Atassi F; Mao C; Masadeh AS; Byrn SR
J Pharm Sci; 2010 Sep; 99(9):3684-97. PubMed ID: 19780126
[TBL] [Abstract][Full Text] [Related]
6. Assessment of defects and amorphous structure produced in raffinose pentahydrate upon dehydration.
Bates S; Kelly RC; Ivanisevic I; Schields P; Zografi G; Newman AW
J Pharm Sci; 2007 May; 96(5):1418-33. PubMed ID: 17455351
[TBL] [Abstract][Full Text] [Related]
7. The Rietveld method as a tool to quantify the amorphous amount of microcrystalline cellulose.
De Figueiredo LP; Ferreira FF
J Pharm Sci; 2014 May; 103(5):1394-9. PubMed ID: 24590572
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the mechanical properties of the crystalline and amorphous forms of a drug substance.
Hancock BC; Carlson GT; Ladipo DD; Langdon BA; Mullarney MP
Int J Pharm; 2002 Jul; 241(1):73-85. PubMed ID: 12086723
[TBL] [Abstract][Full Text] [Related]
9. The effect of physico-chemical properties of the drug on the pharmaceutical availability of piroxicam from pellets.
Pieszczek B; Jachowicz R
Pharm Dev Technol; 2010 Jun; 15(3):241-8. PubMed ID: 22716464
[TBL] [Abstract][Full Text] [Related]
10. Crystallization of amorphous indomethacin during dissolution: effect of processing and annealing.
Greco K; Bogner R
Mol Pharm; 2010 Oct; 7(5):1406-18. PubMed ID: 20459092
[TBL] [Abstract][Full Text] [Related]
11. Cryogenic grinding of indomethacin polymorphs and solvates: assessment of amorphous phase formation and amorphous phase physical stability.
Crowley KJ; Zografi G
J Pharm Sci; 2002 Feb; 91(2):492-507. PubMed ID: 11835208
[TBL] [Abstract][Full Text] [Related]
12. Critical considerations for the qualitative and quantitative determination of process-induced disorder in crystalline solids.
Newman A; Zografi G
J Pharm Sci; 2014 Sep; 103(9):2595-2604. PubMed ID: 24623166
[TBL] [Abstract][Full Text] [Related]
13. Structural characterization and aging of glassy pharmaceuticals made using acoustic levitation.
Benmore CJ; Weber JK; Tailor AN; Cherry BR; Yarger JL; Mou Q; Weber W; Neuefeind J; Byrn SR
J Pharm Sci; 2013 Apr; 102(4):1290-300. PubMed ID: 23381910
[TBL] [Abstract][Full Text] [Related]
14. Toward understanding the evolution of griseofulvin crystal structure to a mesophase after cryogenic milling.
Feng T; Bates S; Carvajal MT
Int J Pharm; 2009 Feb; 367(1-2):16-9. PubMed ID: 19013224
[TBL] [Abstract][Full Text] [Related]
15. Role of water in the physical stability of solid dosage formulations.
Airaksinen S; Karjalainen M; Shevchenko A; Westermarck S; Leppänen E; Rantanen J; Yliruusi J
J Pharm Sci; 2005 Oct; 94(10):2147-65. PubMed ID: 16136577
[TBL] [Abstract][Full Text] [Related]
16. Towards improved solubility of poorly water-soluble drugs: cryogenic co-grinding of piroxicam with carrier polymers.
Penkina A; Semjonov K; Hakola M; Vuorinen S; Repo T; Yliruusi J; Aruväli J; Kogermann K; Veski P; Heinämäki J
Drug Dev Ind Pharm; 2016; 42(3):378-88. PubMed ID: 26065533
[TBL] [Abstract][Full Text] [Related]
17. Studies on the crystallinity of a pharmaceutical development drug substance.
Byard SJ; Jackson SL; Smail A; Bauer M; Apperley DC
J Pharm Sci; 2005 Jun; 94(6):1321-35. PubMed ID: 15858842
[TBL] [Abstract][Full Text] [Related]
18. Segal crystallinity index revisited by the simulation of X-ray diffraction patterns of cotton cellulose Iβ and cellulose II.
Nam S; French AD; Condon BD; Concha M
Carbohydr Polym; 2016 Jan; 135():1-9. PubMed ID: 26453844
[TBL] [Abstract][Full Text] [Related]
19. One-phase crystal disorder in pharmaceutical solids and its implication for solid-state stability.
Clawson JS; Kennedy-Gabb S; Lee AY; Copley RC
J Pharm Sci; 2011 Oct; 100(10):4302-16. PubMed ID: 21590691
[TBL] [Abstract][Full Text] [Related]
20. Preparation and evaluation of solid dispersions of piroxicam and Eudragit S100 by spherical crystallization technique.
Maghsoodi M; Sadeghpoor F
Drug Dev Ind Pharm; 2010 Aug; 36(8):917-25. PubMed ID: 20180658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
